IBI3001 hos deltagere med uoperable, lokalt avancerede eller metastatiske solide tumorer
En fase 1/2 undersøgelse af IBI3001 i deltagere med uoperable, lokalt avancerede eller metastatiske solide tumorer
This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
Studiesteder
-
-
New South Wales
-
Wollongong, New South Wales, Australien, 2500
- Rekruttering
- Wollongong Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Rekruttering
- Cancer Research SA
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
-
-
California
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- START Center for Cancer Research
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
New Jersey
-
East Brunswick, New Jersey, Forenede Stater, 08816
- Rekruttering
- START Center for Cancer Research
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75039
- Rekruttering
- NEXT Oncology
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Aktiv, ikke rekrutterende
- Virginia Cancer Specialists
-
-
-
-
Anhui
-
Hefei, Anhui, Kina, 230022
- Rekruttering
- The First Affiliated Hospital of Anhui Medical University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100021
- Rekruttering
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Beijing, Beijing Municipality, Kina, 100853
- Rekruttering
- Chinese People's Liberation Army General Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350014
- Rekruttering
- Fujian Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Fuzhou, Fujian, Kina, 350005
- Rekruttering
- First Affiliated Hospital, Fujian Medical University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Guangxi
-
Nanning, Guangxi, Kina, 530021
- Rekruttering
- The Affiliated Tumor Hospital of Guangxi Medical University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Rekruttering
- Harbin Medical University Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Henan
-
Anyang, Henan, Kina, 455100
- Rekruttering
- Anyang Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Luoyang, Henan, Kina, 471003
- Rekruttering
- The First Affiliated Hospital of Henan University of Science and Technology
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, Kina, 450008
- Rekruttering
- Henan Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, Kina, 450052
- Rekruttering
- The First Affiliated Hospital of Zhengzhou University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Rekruttering
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Rekruttering
- Xiangya Hospital, Central South University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Rekruttering
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Nanjing, Jiangsu, Kina, 210029
- Rekruttering
- Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330029
- Rekruttering
- Jiangxi Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200120
- Rekruttering
- Shanghai East Hospital, Tongji University School of Medicine
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- West China Hospital, Sichuan University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- Sichuan Cancer Hospital & Institute
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310022
- Rekruttering
- Zhejiang Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Hangzhou, Zhejiang, Kina, 310003
- Rekruttering
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Male or female participants ≥ 18 years old;
- Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- Has an anticipated life expectancy of ≥ 12 weeks;
- Adequate bone marrow and organ function:
- At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
- Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.
Key Exclusion Criteria:
- Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
- Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
- Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
- Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
- Known symptomatic central nervous system (CNS) metastases.
- History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
- History of endotracheal or gastrointestinal stent implantation;
- Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
- Esophageal or gastric varices requiring immediate intervention;
- Not eligible to participate in this study at the discretion of the investigator;
- Do not have adequate treatment washout period before study drug administration. -
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Open-label: IBI3001 monoterapi
|
The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study. IBI3001 is proposed to be administered by intravenous infusion (IV) |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of subjects with adverse events
Tidsramme: 24 months
|
Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria |
24 months
|
|
Number of subjects with clinically significant changes in physical examination results
Tidsramme: 24 months
|
Clinically significant abnormal physical examination findings reported by the investigator. |
24 months
|
|
Number of subjects with clinically significant changes in vital signs
Tidsramme: 24 months
|
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure |
24 months
|
|
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
Tidsramme: 24 months
|
Dose limiting toxicity (DLT) to establish MTD or RP2D |
24 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma concentration (Cmax) of IBI3001
Tidsramme: 24 months
|
Plasma concentration of IBI3001 for single and multiple doses. |
24 months
|
|
Area under the curve (AUC) of IBI3001
Tidsramme: 24 months
|
AUC of IBI3001 for single and multiple doses |
24 months
|
|
Time to maximum concentration (Tmax) of IBI3001
Tidsramme: 24 months
|
Tmax of IBI3001 for single and multiple doses. |
24 months
|
|
Clearance (CL) of IBI3001
Tidsramme: 24 months
|
Clearance of IBI3001 from the plasma |
24 months
|
|
Volume of distribution (V) of IBI3001
Tidsramme: 24 months
|
Apparent volume of distribution of IBI3001 |
24 months
|
|
Half-life (T1/2) of IBI3001
Tidsramme: 24 months
|
T1/2 of IBI3001 for single and multiple doses |
24 months
|
|
Immunogenicity of IBI3001
Tidsramme: 24 months
|
Incidence of anti-drug (IBI3001) antibody |
24 months
|
|
Objective response rate (ORR)
Tidsramme: 24 months
|
ORR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Duration of response (DoR)
Tidsramme: 24 months
|
DoR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Disease control rate (DCR)
Tidsramme: 24 months
|
DCR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Time to response (TTR)
Tidsramme: 24 months
|
TTR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Progression free survival (PFS)
Tidsramme: 24 months
|
PFS as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Overall survival (OS)
Tidsramme: 24 months
|
Overall survival. |
24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CIBI3001A101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .